Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results. TOP Financial Group Limited (NASDAQ: TOP) jumped 52.4% to close at $19.25. FlexShopper, Inc. (NASDAQ: FPAY) jumped 47.3% to close at $1.65 after reporting Q2 results. Timber Pharmaceuticals, Inc. (NYSE: TMBR) shares gained 37.3% to close at $0.1483 on Thursday. Timber Pharmaceuticals recently announced closing of $8.0 million public offering. Veru Inc (NASDAQ: VERU) shares jumped 36% to close at $16.01 after the company reported Q3 earnings results. Nymox Pharmaceutical Corporation (NASDAQ: NYMX) jumped 35.6% to close at $0.61. Vacasa, Inc. (NASDAQ: VCSA) shares gained 33.2% to close at $4.05 after posting upbeat quarterly sales. AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) jumped 33% to close at $0.3126. The company on Wednesday announced acceptance for a podium presentation at the ANESTHESIOLOGY 2022 Annual Meeting. ShiftPixy, Inc. (NASDAQ: PIXY) gained 32.3% to close at $0.2620. Esports Entertainment Group, Inc. (NASDAQ: GMBL) shares gained 32% to close at $0.60 after Massachusetts Governor Baker on Wednesday signed a sports betting bill into law. PARTS iD, Inc. (NYSE: ID) gained 31.7% to close at $1.83. PARTS iD recently posted a Q2 loss of $0.03 per share. voxeljet AG (NASDAQ: VJET) jumped 31.3% to settle at $6.00. Enovix Corporation (NASDAQ: ENVX) climbed 30.8% to close at $21.13 following Q2 results. CASI Pharmaceuticals, Inc. (NASDAQ: CASI) jumped 29.6% to close at $3.90. CASI Pharmaceuticals is set to host a conference call reviewing the Q2 financial results on Friday, August 12th, 2022. Butterfly Network, Inc. (NYSE: BFLY) climbed 28.8% to settle at $8.61. UpHealth, Inc. (NYSE: UPH) jumped 28.8% to close at $0.89. Gamida Cell Ltd. (NASDAQ: GMDA) gained 28.4% to close at $3.39. Gamida Cell announced dosing of first patient in company-sponsored Phase 1/2 study of NK cell therapy candidate GDA-201. Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) shares jumped 26.3% to close at $1.68 after the company posted a narrower Q2 loss. T2 Biosystems, Inc. (NASDAQ: TTOO) shares climbed 26.3% to close at $0.1995. T2 Biosystems shares jumped over 30% on Wednesday after the company on Tuesday announced it will explore the potential to develop a rapid molecular diagnostic test for monkeypox. Humacyte, Inc. (NASDAQ: HUMA) gained 26.1% to settle at $4.40. 5E Advanced Materials Inc. (NASDAQ: FEAM) gained 25.6% to close at $19.72 after the company announced Bluescape will invest $60 million in 5E's secured convertible notes. SmileDirectClub, Inc. (NASDAQ: SDC) gained 24.6% to close at $1.62 as the stock reversed from weakness earlier in the week. The stock fell Monday after the company reported worse-than-expected Q2 EPS and sales results and issued FY22 sales guidance below estimates. Missfresh Limited (NASDAQ: MF) surged 24% to settle at $0.1976. Arhaus, Inc. (NASDAQ: ARHS) surged 23.9% to close at $7.93 after the company reported better-than-expected Q2 adjusted EPS and sales results and raised FY22 sales guidance above estimates. Midwest Holding Inc. (NASDAQ: MDWT) gained 23.7% to settle at $14.88. Dawson Geophysical Company (NASDAQ: DWSN) climbed 22.9% to close at $1.6350. Astra Space, Inc. (NASDAQ: ASTR) rose 22.7% to close at $1.73 after board member Michael Lehman reported a large insider buy on August 10 in a Form4 filing. Accuray Incorporated (NASDAQ: ARAY) jumped 21.1% to settle at $2.64 after the company reported better-than-expected Q4 EPS and sales results. SunOpta Inc. (NASDAQ: STKL) jumped 20.2% to close at $10.73. SunOpta raised its FY22 revenue guidance. Warby Parker Inc. (NYSE: WRBY) gained 19.2% to close at $16.90 after the company reported Q2 EPS results were higher year over year and better-than-expected Q2 sales results. AST SpaceMobile, Inc. (NASDAQ: ASTS) gained 18.7% to close at $10.87. AST SpaceMobile recently announced that its test satellite has arrived at the launch location for its upcoming planned launch. Quanterix Corporation (NASDAQ: QTRX) surged 18.7% to close at $10.16. Quanterix Director Paul Meister reported the purchase of 234,304 shares at an average price of $8.53 per share ...

Gainers Timber Pharmaceuticals, Inc. (NYSE: TMBR) shares rose 63.8% to $0.1769. Timber Pharmaceuticals recently announced closing of $8.0 million public offering. T2 Biosystems, Inc. (NASDAQ: TTOO) shares jumped 50.6% to $0.2379. T2 Biosystems shares jumped over 30% on Wednesday after the company on Tuesday announced it will explore the potential to develop a rapid molecular diagnostic test for monkeypox. FlexShopper, Inc. (NASDAQ: FPAY) rose 38.6% to $1.5519 after reporting Q2 results. Esports Entertainment Group, Inc. (NASDAQ: GMBL) shares jumped 33.6% to $0.6078 after Massachusetts Governor Baker on Wednesday signed a sports betting bill into law. AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) surged 30.8% to $0.3075. The company on Wednesday announced acceptance for a podium presentation at the ANESTHESIOLOGY 2022 Annual Meeting. Veru Inc (NASDAQ: VERU) shares gained 30.5% to $15.36 after the company reported Q3 earnings results. SmileDirectClub, Inc. (NASDAQ: SDC) jumped 29% to $1.68 as the stock reversed from weakness earlier in the week. The stock fell Monday after the company reported worse-than-expected Q2 EPS and sales results and issued FY22 sales guidance below estimates. Enovix Corporation (NASDAQ: ENVX) rose 28.6% to $20.81 following Q2 results. CASI Pharmaceuticals, Inc. (NASDAQ: CASI) gained 27.9% to $3.85. CASI Pharmaceuticals is set to host a conference call reviewing the Q2 financial results on Friday, August 12th, 2022. AST SpaceMobile, Inc. (NASDAQ: ASTS) jumped 27.5% to $11.68. AST SpaceMobile recently announced that its test satellite has arrived at the launch location for its upcoming planned launch. Nymox Pharmaceutical Corporation (NASDAQ: NYMX) gained 27% to $0.5713. Vacasa, Inc. (NASDAQ: VCSA) shares rose 26.4% to $3.8410 after posting upbeat quarterly sales. Inotiv, Inc. (NASDAQ: NOTV) jumped 25.8% to $26.08 after the company reported better-than-expected Q3 sales results. Absci Corporation (NASDAQ: ABSI) gained 25.7% to $5.28 after the company posted a narrower Q2 loss. Matterport, Inc. (NASDAQ: MTTR) climbed 24.9% to $6.48 after the company reported better-than-expected Q2 EPS results and issued Q3 and FY22 EPS and sales guidance above estimates. Digital Media Solutions, Inc. (NYSE: DMS) gained 24.5% to $1.4699. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results Wave Life Sciences Ltd. (NASDAQ: WVE) jumped 24.2% to $3.1687 after the company reported Q2 EPS results were up year over year. Sonder Holdings Inc. (NASDAQ: SOND) gained 24% to $2.6450 after the company reported better-than-expected Q2 sales results. Astra Space, Inc. (NASDAQ: ASTR) gained 23.7% to $1.7450 after board member Michael Lehman reported a large insider buy on August 10 in a Form4 filing. Direct Digital Holdings, Inc. (NASDAQ: DRCT) shares gained 22% to $3.1121 after the company reported better-than-expected Q2 EPS results. SunOpta Inc. (NASDAQ: STKL) gained 22.2% to $10.91. SunOpta raised its FY22 revenue guidance. Arhaus, Inc. (NASDAQ: ARHS) jumped 21.8% ...

SAN DIEGO, June 17, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology, today announced that on June 17, 2022, it received a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), stating that the Company is not in compliance with the minimum bid price requirement ("Minimum Bid Requirement") of US$1.00 per share under the Nasdaq Listing Rule 5450(a)(1) based upon the closing bid price of the Company’s common stock for the 30 consecutive business days prior to the date of the Notice. The Notice has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq.

SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the following appointments to the Board, effective June 5, 2022:

SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Matt Angel, Ph.D., Co-Founder, Chairman, and CEO of Factor Bioscience Inc., as Interim Chief Executive Officer and President. He will replace Howard J. Federoff, M.D., Ph.D., Chief Executive Officer and President, who departs to focus on building a new venture. The Company also announces the appointment of Andrew Jackson as Chief Financial Officer.

SAN DIEGO, May 27, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that it received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”), stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 (the “Quarterly Report”), Brooklyn is no longer in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission. The Notice has no immediate effect on the listing of Brooklyn’s shares on Nasdaq.

SAN DIEGO, April 15, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced financial results for the fourth quarter and year ended December 31, 2021.

NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that it has closed its previously announced private placement with a leading healthcare investor. The gross proceeds to Brooklyn from the private placement, before deducting the placement agent’s fees and other estimated fees and expenses related to the offering payable by Brooklyn, were approximately $12 million. Brooklyn intends to use the net proceeds from the private placement for general working capital purposes.

NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces the appointment of two new members of the Company’s Board of Directors.

NEW YORK, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces that 18 new patents were issued and 17 new patent applications were filed in 2021. The intellectual property is owned by Factor Bioscience (“Factor”) and exclusively licensed to Brooklyn for various fields of therapeutic use. The newly-issued patents encompass those covering the Company’s mRNA-based cellular reprogramming and gene editing technology, as well as nucleic acid delivery using Brooklyn’s ToRNAdo™ lipid nanoparticle technology (LNP).

NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces that Brooklyn has been named to be part of the Nasdaq Biotechnology Index (Nasdaq:NBI), effective December 20, 2021.

Company Continues to Secure Resources to Build Gene Editing/Cell Therapy Drug Development Platform Company Continues to Secure Resources to Build Gene Editing/Cell Therapy Drug Development Platform